Alzamend Neuro, Inc. filed a Form 8-K on November 17, 2026, disclosing that Massachusetts General Hospital terminated the bipolar disorder statement of work under the companies' clinical trial agreement after the FDA declined to support the company's proposed Phase II trial approach for AL001.

Key Highlights

  • BD SOW terminated: MGH delivered written notice on November 11, 2026, terminating the bipolar disorder statement of work after the trial was paused and MGH could not hold staff in reserve for the anticipated period.
  • FDA feedback received: On October 15, 2026, the FDA stated it did not support the proposed approach and indicated that "efficacy and safety trials may be more appropriate to support a New Drug Application."
  • Trial paused October 21, 2026: The company paused the BD Clinical Trial six days after receiving the FDA's written feedback to assess its options.
  • Refund of approximately $25,000: The company will receive a refund of approximately $25,000 from MGH for funds previously paid in connection with the BD Clinical Trial but not utilized.
  • Type B FDA meeting planned: The company intends to request a Type B meeting with the FDA and anticipates receiving feedback by the end of the second quarter of 2027.
  • Healthy Patient Clinical Trial unaffected: The company expects to finalize the clinical study report and announce final results for the healthy subjects trial in December 2026.
  • Master agreement remains intact: According to the filing, the termination of the BD SOW "has not impact on the Agreement, which otherwise remains in full and effect."

Alzamend Neuro Discloses BD Trial Termination and Pivot Toward Phase III Path

According to the filing, Alzamend Neuro (NASDAQ:ALZN) entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital ("MGH") in July 2024 to conduct five Phase II clinical trials of AL001, covering healthy subjects and patients with Alzheimer's Disease, bipolar disorder ("BD"), major depressive disorder ("MDD"), and post-traumatic stress disorder ("PTSD"). The company had executed statements of work for healthy subjects and BD patients. The BD Clinical Trial was initiated in March 2026.

The filing states that MGH advised the company that recruitment proved challenging because eligibility criteria excluded patients with co-morbidities - including diabetes, metabolic syndrome, cardiovascular disease, and anxiety disorders - that are "highly prevalent in this patient population." The company requested that the FDA allow modified enrollment criteria. In response, the FDA, in its October 15, 2026 written feedback, stated that "it does not appear that you are designing the aforementioned trials to be adequate and well-controlled studies that would be capable of providing substantial evidence of effectiveness for the proposed indications," and suggested efficacy and safety trials aimed at supporting a New Drug Application may be more appropriate.

The company disclosed that, based on this feedback, it plans to request a Type B meeting with the FDA to seek input on a revised clinical development plan. That plan is "expected to include ceasing Phase II trials of AL001 and moving directly into a Phase III efficacy and safety trial in BD that would support an NDA." The company is preparing a briefing package and anticipates receiving FDA feedback by the end of the second quarter of 2027. The filing notes that the company still plans to pursue further clinical studies of AL001 in BD, MDD, PTSD, and Alzheimer's following FDA guidance.

What Was Disclosed

Alzamend Neuro disclosed the November 11, 2026 termination of its BD statement of work with MGH, the FDA's October 2026 written feedback questioning the Phase II trial design, the company's plan to pursue a Type B FDA meeting, and an expected approximately $25,000 refund from MGH.